Comparative Evaluation of Efficacy of Modified Ashmaghnasveda (Stone Therapy) and Choornapindasveda in Management of Katigraha (Lumbar spondylosis)

Anup Jain *

Department of Panchakarma, Mahatma Gandhi Ayurveda College Hospital and Research Centre (MGACH&RC), Salod (Hirapur), Datta Meghe Institute of Medical Sciences, Sawangi (Meghe) Wardha, Maharashtra, India.

Punam Sawarkar

Department of Panchakarma, Mahatma Gandhi Ayurveda College Hospital and Research Centre (MGACH&RC), Salod (Hirapur), Datta Meghe Institute of Medical Sciences, Sawangi (Meghe) Wardha, Maharashtra, India.

*Author to whom correspondence should be addressed.


Abstract

Background: Katigraha is one of the most common illnesses affecting the Kati area, in which Vata gets are unbalanced in their own sthana (seat), resulting in Graha (stiffness) and Ruja (pain). Lumbar Spondylosis is a disease that causes back discomfort caused by spine movement and is accompanied by rigidity. Ashmaghnasveda is a key svedana treatment that helps with vataja, particularly Sama vataja and vatakaphaja illnesses. In this project, a structurally modified form of Ashmaghnasveda will be employed to produce ekangasveda. The goal of this study was to assess the efficacy of modified Ashmaghnasveda (stone therapy) and churnapindasveda in the treatment of Katigraha (lumbar spondylosis).

Methodology: A total of 64 patients will be enrolled, and they will be evenly divided into two groups. Modified Ashmaghnasveda will be performed for 14 days in GroupA(Interventional). Churnapindasveda will be performed for 14 days in GroupB (comparator group). Expected Results: The objective parameters will be monitored and documented as they change. Conclusion: Based on the information gathered, conclusions will be reached.

Keywords: Ashmaghnasveda, katigraha, lumbar spondylosis, ashmaghnasveda


How to Cite

Jain, Anup, and Punam Sawarkar. 2021. “Comparative Evaluation of Efficacy of Modified Ashmaghnasveda (Stone Therapy) and Choornapindasveda in Management of Katigraha (Lumbar Spondylosis)”. Journal of Pharmaceutical Research International 33 (62A):23-31. https://doi.org/10.9734/jpri/2021/v33i62A35145.

Downloads

Download data is not yet available.